Unlocking Access to Precision Therapies: Insights from the Upcoming Xtalks Webinar
Unlocking Access to Precision Therapies: Insights from the Upcoming Xtalks Webinar
The landscape of medicine is rapidly evolving with the introduction of precision therapies that leverage biomarker data to tailor treatments. However, while these advancements in clinical options are impressive, they do not guarantee commercial success. In the U.S. healthcare system, therapies that are guided by biomarkers and those that utilize companion diagnostics often encounter significant hurdles concerning accessibility.
As medical science advances, so too must the strategies employed by developers and stakeholders in the healthcare market. The upcoming webinar hosted by Xtalks, titled "From Biomarker to Market: Optimizing Access for Precision Therapies", scheduled for June 30, 2026, aims to address these pressing issues. Through this free online event, attendees will gain invaluable insights on how to effectively navigate the complex web of payer expectations associated with biomarker-driven therapies.
Key Focus Areas of the Webinar
The Xtalks webinar will cover critical topics, including:
1. Navigating U.S. Access Barriers: The session will provide practical guidance on how to address the evolving access barriers within the U.S. healthcare landscape, particularly for small, biomarker-defined populations.
2. Addressing Evidence Gaps: A significant theme will be the identification and resolution of evidence gaps that often challenge the acceptance of precision therapies by payers. This is especially important when dealing with small patient populations that may not meet traditional clinical trial criteria.
3. Leveraging Real-World Data: Participants will learn how to employ real-world data and external comparators to validate endpoints and substantiate the value of precision therapies, thereby enhancing their market acceptance.
4. Patient-Centered Evidence Integration: The webinar will highlight the importance of integrating patient-focused data to fortify differentiation and relevance in decision-making frameworks.
5. Building Multi-Stakeholder Evidence Strategies: The session will assist attendees in constructing comprehensive, multi-stakeholder strategies that address the unique needs of rare oncology and neurology markets.
Expert Speakers
The webinar will feature an esteemed panel of speakers from Thermo Fisher Scientific and PPD Evidera, including:
- - Adam Petrich, MD, Vice President of Oncology, Medical Science and Strategy
- - Priya Jain, MS, MBA, Executive Director of PPD Evidera Health Economics & Market Access
- - John Hamlet, Executive Director of Neuroscience Pillar Head
- - Amanda Pulfer, BA, Executive Director of Integrated Solutions, RWE, PPD Evidera
- - Elizabeth Dansie Bacci, PhD, Senior Research Scientist, PPD Evidera
This assembly of experts will share their wealth of knowledge and experiences, offering participants a framework for transforming innovative, precision therapies into payer-relevant value propositions.
Conclusion
By the end of the session, attendees will be equipped with a comprehensive understanding of the strategies needed to convert promising scientific advancements into evident clinical benefits recognized by payers. This initiative aims to improve access, enhance reimbursement outcomes, and foster commercial sustainability for precision therapies in the evolving healthcare environment.
For those interested in joining this informative session, registration details can be found at Xtalks. Don’t miss this opportunity to deepen your understanding of the intricacies involved in bringing precision medicine from lab to market successfully.
Stay informed, connected, and ready for the future of healthcare with Xtalks – your partner in navigating the complexities of the life science sector.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.